Vorinostat Patent Expiration

Vorinostat is Used for treating cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL). It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc in its drug Zolinza on Oct 6, 2006.


Vorinostat Patents

Given below is the list of patents protecting Vorinostat, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zolinza US8450372 Formulations of suberoylanilide hydroxamic acid and methods for producing same Mar 18, 2028 Msd Sub Merck
Zolinza US7456219 Polymorphs of suberoylanilide hydroxamic acid Mar 11, 2027 Msd Sub Merck
Zolinza US8093295 Formulations of suberoylanilide hydroxamic acid and methods for producing the same May 16, 2026

(Expired)

Msd Sub Merck
Zolinza US7399787 Methods of treating cancer with HDAC inhibitors Feb 09, 2025

(Expired)

Msd Sub Merck
Zolinza US7851509 Polymorphs of suberoylanilide hydroxamic acid Feb 21, 2024

(Expired)

Msd Sub Merck
Zolinza US7652069 Polymorphs of suberoylanilide hydroxamic acid Mar 04, 2023

(Expired)

Msd Sub Merck
Zolinza US7732490 Methods of treating cancer Mar 04, 2023

(Expired)

Msd Sub Merck
Zolinza US8067472 Methods of treating Hodgkin's and non-Hodgkin's lymphoma Mar 04, 2023

(Expired)

Msd Sub Merck
Zolinza US8101663 Polymorphs of suberoylanilide hydroxamic acid Mar 04, 2023

(Expired)

Msd Sub Merck
Zolinza USRE38506 Potent inducers of terminal differentiation and methods of use thereof Nov 29, 2013

(Expired)

Msd Sub Merck



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vorinostat's patents.

Given below is the list recent legal activities going on the following patents of Vorinostat.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 10 Oct, 2024 US8450372
Expire Patent 01 Jan, 2024 US8067472
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8067472
Payment of Maintenance Fee, 12th Year, Large Entity 14 Jun, 2023 US8093295
Payment of Maintenance Fee, 12th Year, Large Entity 11 May, 2022 US7851509
Payment of Maintenance Fee, 12th Year, Large Entity 11 Nov, 2021 US7732490
Payment of Maintenance Fee, 12th Year, Large Entity 10 Jun, 2021 US7652069
Payment of Maintenance Fee, 8th Year, Large Entity 28 Sep, 2020 US8450372
Payment of Maintenance Fee, 12th Year, Large Entity 15 Apr, 2020 US7456219
Payment of Maintenance Fee, 12th Year, Large Entity 18 Dec, 2019 US7399787


Vorinostat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Vorinostat:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer Institut Claudius Regaud NA TERMINATED
(Sep 1, 2026)
PHASE1
An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome Unravel Biosciences, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
The DART DELIVER-02 Study University of North Carolina, Chapel Hill NA SUSPENDED
(Aug 1, 2026)
PHASE1
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab New Approaches to Neuroblastoma Therapy Consortium NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides Virogen Biotechnology Inc. NA WITHDRAWN
(May 1, 2026)
PHASE2


Vorinostat Generic API Manufacturers

Given below is the list of companies who have filed for Vorinostat generic, along with the locations of their manufacturing plants worldwide.